Arquitectura e industria hidroeléctrica : las obras de Ignacio Álvarez Castelao y Juan José Elorza para Electra de Viesgo en Asturias

La construcción de infraestructuras hidráulicas constituye uno de los ejes mejor conocidos de la política económica del desarrollismo industrial en España desde comienzos de los años cincuenta. Sin embargo, pese a su elevado número e interés, éstas apenas se han estudiado desde el punto de vista arquitectónico. Este artículo estudia las características de las obras hidráulicas que proyectaron juntos el arquitecto Ignacio Álvarez Castelao y el ingeniero Juan José Elorza para la compañía Electra de Viesgo SA en Asturias y en Palencia durante los años cincuenta y sesenta del siglo XX. Todos los casos mencionados tienen en común la fructífera colaboración de distintos profesionales en un equipo multidisciplinar en el que se incluyeron la bellas artes

Contributions to hand gesture recognition on the basis of range data

Tesis doctoral inédita, leída en la Universidad Autónoma de Madrid, Escuela Politécnica Superior. Fecha de lectura: octubre de 2012

Real-time motion-based hand gestures recognition from time-of-flight video

The final publication is available at Springer via http://dx.doi.org/10.1007/s11265-015-1090-5This paper presents an innovative solution based on Time-Of-Flight (TOF) video technology to motion patterns detection for real-time dynamic hand gesture recognition. The resulting system is able to detect motion-based hand gestures getting as input depth images. The recognizable motion patterns are modeled on the basis of the human arm anatomy and its degrees of freedom, generating a collection of synthetic motion patterns that is compared with the captured input patterns in order to finally classify the input gesture. For the evaluation of our system a significant collection of gestures has been compiled, getting results for 3D pattern classification as well as a comparison with the results using only 2D informatio

De molinos harineros a fábricas de luz: arquitectura e ingeniería hidráulica en el norte de Madrid

Comunicación presentada al 8º Congreso Nacional de Molinología que recoge los trabajos de investigación arquitectónica y etnográfica desarrollados en distintos municipios del norte de la Comunidad de Madrid

Extensibility of adaptation capabilities in the CAIN content adaptation engine

Also published online by CEUR Workshop Proceedings (CEUR-WS.org, ISSN 1613-0073)This paper describes the extensibility mechanism that has been incorporated to the CAIN Adaptation Engine, that provides audiovisual content adaptation based on user preferences, network capabilities and terminal limitations. The integration of new adaptation modules needs no code modifications in the core system, so it does not have to be recompiled for adding or modifying adaptation modules.This work is partially supported by the European Commission 6th Framework Program under project FP6-001765 (aceMedia). This work is also supported by the Ministerio de Ciencia y Tecnología of the Spanish Government under project TIN2004-07860 (MEDUSA) and by the Comunidad de Madrid under project P-TIC-0223-0505 (PROMULTIDIS). The authors want to thank Víctor Fernández-Carbajales for successful testing of the extensibility mechanism

Sarcoma treatment in the era of molecular medicine

Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.Peer reviewe

Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism

Background Atrial fibrillation (AF) may exist before or occur early in the course of pulmonary embolism (PE). We determined the PE outcomes based on the presence and timing of AF. Methods and Results Using the data from a multicenter PE registry, we identified 3 groups: (1) those with preexisting AF, (2) patients with new AF within 2 days from acute PE (incident AF), and (3) patients without AF. We assessed the 90-day and 1-year risk of mortality and stroke in patients with AF, compared with those without AF (reference group). Among 16 497 patients with PE, 792 had preexisting AF. These patients had increased odds of 90-day all-cause (odds ratio [OR], 2.81; 95% CI, 2.33-3.38) and PE-related mortality (OR, 2.38; 95% CI, 1.37-4.14) and increased 1-year hazard for ischemic stroke (hazard ratio, 5.48; 95% CI, 3.10-9.69) compared with those without AF. After multivariable adjustment, preexisting AF was associated with significantly increased odds of all-cause mortality (OR, 1.91; 95% CI, 1.57-2.32) but not PE-related mortality (OR, 1.50; 95% CI, 0.85-2.66). Among 16 497 patients with PE, 445 developed new incident AF within 2 days of acute PE. Incident AF was associated with increased odds of 90-day all-cause (OR, 2.28; 95% CI, 1.75-2.97) and PE-related (OR, 3.64; 95% CI, 2.01-6.59) mortality but not stroke. Findings were similar in multivariable analyses. Conclusions In patients with acute symptomatic PE, both preexisting AF and incident AF predict adverse clinical outcomes. The type of adverse outcomes may differ depending on the timing of AF onset.info:eu-repo/semantics/publishedVersio

Famílies botàniques de plantes medicinals

Facultat de Farmàcia, Universitat de Barcelona. Ensenyament: Grau de Farmàcia, Assignatura: Botànica Farmacèutica, Curs: 2013-2014, Coordinadors: Joan Simon, Cèsar Blanché i Maria Bosch.Els materials que aquí es presenten són els recull de 175 treballs d’una família botànica d’interès medicinal realitzats de manera individual. Els treballs han estat realitzat per la totalitat dels estudiants dels grups M-2 i M-3 de l’assignatura Botànica Farmacèutica durant els mesos d’abril i maig del curs 2013-14. Tots els treballs s’han dut a terme a través de la plataforma de GoogleDocs i han estat tutoritzats pel professor de l’assignatura i revisats i finalment co-avaluats entre els propis estudiants. L’objectiu principal de l’activitat ha estat fomentar l’aprenentatge autònom i col·laboratiu en Botànica farmacèutica

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio